Clinical trials: Lenvatinib
Carcinoma, Hepatocellular, Carcinoma
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
The primary purpose of this study to continue follow-up of participants enrolled in the study E7080-M081-504 (NCT03663114) of lenvima capsules and to evaluate the overall survival of participants with hepatocellular carcinoma.
- Conditions
- Carcinoma, Hepatocellular, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms
- Trial name
- NCT04008082
- Testing
- Lenvatinib
- Where
- 2 sites in Japan
- Volunteers
- 412 people
- Sponsor
- Eisai Co., Ltd.
Advanced Solid Tumor, Metastatic Solid Tumor
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma
- Trial name
- NCT04977453
- Testing
- GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib
- Where
- 13 sites in United States, South Korea
- Volunteers
- 317 people
- Sponsor
- GI Innovation, Inc.
Hepatocellular Carcinoma (HCC), Downstaging
Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging
The goal of this observational study is to learn about the long-term treatment outcomes for patients with initially unresectable hepatocellular carcinoma (HCC) who achieve successful downstaging with the combination therapy of…
- Conditions
- Hepatocellular Carcinoma (HCC), Downstaging, Liver Resection, Lenvatinib
- Trial name
- NCT07581769
- Testing
- Liver resection, TACE plus Lenvatinib and PD1 inhibiter
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Endometrial Cancer, Mismatch Repair-Proficient
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants
- Conditions
- Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer
- Trial name
- NCT05263492
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Virginia Commonwealth University
Endometrial Cancer, Endometrial Adenocarcinoma
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with lenvatinib in patients with advanced endometrial cancer.
- Trial name
- NCT05824481
- Testing
- Cadonilimab, Lenvatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Advanced Endometrial Cancer
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab…
- Trial name
- NCT05112991
- Testing
- Envafolimab+Lenvatinib, Envafolimab
- Where
- 19 sites in China
- Volunteers
- 108 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
NSCLC (Non-small Cell Lung Cancer)R
A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation
This interventional study will evaluate the effectiveness, safety, and tolerability of pembrolizumab in combination with lenvatinib in adults with metastatic non-small cell lung cancer (NSCLC) who have a confirmed RET gene…
- Trial name
- LPR-2 (NCT07809256)
- Testing
- lenvatinib pembrolizumab
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- EuroCityClinic LLC
Advanced HCC
Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC
The ORR of the lenvatinib combination (lenvatinib combined with PD-1 inhibitor) was largely similar to that of the "A+T" combination (bevacizumab and atelelizumab).
- Trial name
- NCT05831969
- Testing
- Lenalidomide
- Volunteers
- 23 people
- Sponsor
- Shenyang Tenth People's Hospital
Ovarian Cancer, Epithelial
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian…
- Trial name
- NCT05422183
- Testing
- Envafolimab, Lenvatinib, VP-16
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhongda Hospital
Advanced Solid Tumors, Lymphomas
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
The purpose of this study was to determine the metabolism and elimination of 14C-lenvatinib in participants with advanced solid tumors or lymphomas, who were unsuitable for, or had failed, existing therapies.
- Trial name
- NCT02578316
- Testing
- Lenvatinib
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Eisai Inc.
Unresectable Hepatocellular Carcinoma (HCC)
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
The primary purpose of this study is to assess the single- and multiple-dose pharmacokinetic (PK) profile of lenvatinib in Chinese participants with unresectable Hepatocellular Carcinoma (HCC).
- Trial name
- NCT02953743
- Testing
- Lenvatinib
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Eisai Co., Ltd.
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- NCT03829332
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 162 sites in United States, Australia and 17 more
- Volunteers
- 623 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers
The study will be conducted in adult healthy participants and will consist of two phases: Prerandomization and Randomization. The Prerandomization Phase will consist of 2 periods: a Screening Period and a Baseline Period.
- Trial name
- NCT02792829
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Melanoma
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus lenvatinib in patients with melanoma liver metastasis.
- Trial name
- NCT05406466
- Testing
- Tislelizumab, Lenvatinib, Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Initially Unresectable Hepatocellular Carcinoma
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular…
- Trial name
- NCT07480382
- Testing
- Liver Venous Deprivation (LVD), Conventional Transarterial Chemoembolization(C-TACE), Tislelizumab combined with Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hong Wu
Hepatocellular Carcinoma
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Lenvatinib plus Toripalimab in patients with advanced hepatocellular carcinoma and to analyze potential biomarkers of therapeutic response.
- Trial name
- NCT04368078
- Testing
- Toripalimab plus Lenvatinib
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody HX008 plus bevacizumab or lenvatinib in the first-line treatment of patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT04741165
- Testing
- HX008, Bevacizumab, Lenvatinib
- Where
- 13 sites in China
- Volunteers
- 72 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Esophageal Squamous Carcinoma
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
This is a single-arm, exploratory clinical study.
- Trial name
- NCT07490002
- Testing
- Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel
- Volunteers
- 33 people
- Sponsor
- Changhai Hospital
Hepatocellular Carcinoma (HCC)
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable…
- Trial name
- NCT01761266
- Testing
- Lenvatinib, Sorafenib
- Where
- 186 sites in United States, Australia and 19 more
- Volunteers
- 954 people
- Sponsor
- Eisai Limited
Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable…
- Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
- Trial name
- GDFATHERHCC01 (NCT07219459)
- Testing
- Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 104 people
- Sponsor
- CatalYm GmbH